CLINICAL TRIALS PROFILE FOR AMNESTEEM
✉ Email this page to a colleague
All Clinical Trials for AMNESTEEM
Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
---|---|---|---|---|---|---|
NCT00004188 ↗ | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | Completed | National Cancer Institute (NCI) | Phase 3 | 2001-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma. |
NCT00004188 ↗ | Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma | Completed | Children's Oncology Group | Phase 3 | 2001-02-01 | RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell transplantation with untreated peripheral stem cells following combination chemotherapy in treating patients with neuroblastoma. |
NCT00005576 ↗ | Monoclonal Antibody Therapy With Sargramostim and Interleukin-2 in Treating Children With Neuroblastoma | Completed | National Cancer Institute (NCI) | Phase 1 | 2001-01-01 | Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Colony-stimulating factors such as sargramostim may increase the number of immune cells found in bone marrow or peripheral blood. Interleukin-2 may stimulate a person's white blood cells to kill cancer cells. Combining monoclonal antibody therapy with sargramostim or interleukin-2 may kill more tumor cells. Phase I trial to study the effectiveness of monoclonal antibody therapy given with sargramostim and interleukin-2 in treating children with neuroblastoma who have just completed bone marrow or peripheral stem cell transplantation |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for AMNESTEEM
Condition Name
Clinical Trial Locations for AMNESTEEM
Trials by Country
Clinical Trial Progress for AMNESTEEM
Clinical Trial Phase
Clinical Trial Sponsors for AMNESTEEM
Sponsor Name